Search results
400 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Able Wealth Management LLC
ETF DAILY NEWS· 6 days agoAble Wealth Management LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) in the 4th quarter, HoldingsChannel.com reports.
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
Pharmaceutical Technology via Yahoo Finance· 10 hours agoAstraZeneca has received approval for Truqap (capivasertib) in combination with Faslodex...
Wellington Management Group LLP Has $3.33 Billion Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 4 days agoWellington Management Group LLP decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.1% during the 4th quarter, according ...
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer - AstraZeneca (NASDAQ:AZN)
Benzinga· 4 days agoAstraZeneca plc’s AZN cancer drug, Imfinzi (durvalumab), in conjunction with standard chemotherapy,...
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Benzinga via Yahoo Finance· 3 days agoAstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug...
One AstraZeneca Insider Raised Stake By 50% In Previous Year
Simply Wall St. via Yahoo Finance· 3 days agoViewing insider transactions for AstraZeneca PLC's (LON:AZN ) over the last year, we see that...
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
Zacks via Yahoo Finance· 1 day agoThe European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for...
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
WHTC 1450 Holland· 4 days ago(Reuters) - AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial - ...
Benzinga· 3 days agoTuesday, AstraZeneca Plc AZN announced topline data from the CAPItello-290 Phase 3 trial for Truqap...
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression...
Benzinga· 4 days agoAstraZeneca Plc AZN released data from the ECHO Phase 3 trial of Calquence (acalabrutinib) plus...